

# Peptide Macrocyclization via Cu-catalyzed 1,3-Dipolar Cycloaddition of Azomethine Ylides

Enrique Gallent,<sup>a</sup> Inés Alonso,<sup>a,b</sup> Juan C. Carretero,<sup>a,b</sup> Nuria Rodríguez,<sup>\*a,b</sup> and Javier Adrio<sup>\*a,b</sup>

<sup>a</sup> Departamento de Química Orgánica, Facultad de Ciencias. C/ Francisco Tomás y Valiente 7, Universidad Autónoma de Madrid, 28049 Madrid (Spain).

<sup>b</sup> Institute for Advanced Research in Chemical Sciences (IAdChem) and Center for Innovation in Advanced Chemistry (ORFEO-CINQA). Universidad Autónoma de Madrid, 28049 Madrid (Spain)

---

**ABSTRACT:** Cyclic peptides are highly valued synthetic targets in organic and medicinal chemistry. The development of new synthetic methodologies for peptide macrocyclization, different from classical lactamization, is essential for the progress of the field. Herein, we report an efficient diastereoselective macrocyclization strategy for the synthesis of cyclic peptides using 1,3-dipolar cycloaddition of azomethine ylides. Linear precursors of different length and bearing diverse amino acids have shown to be compatible with this method (26 examples), giving good yields and almost complete diastereoselectivity. The DFT calculations suggest a stepwise mechanism in which Cu plays a key role in reagents preorganization.

---

Cyclic peptides are intriguing molecules widely present in nature with applications ranging from drug development to nanomaterials or food additives.<sup>1</sup> Compared to their linear counterparts, cyclic peptides provide a more versatile platform for exploring chemical space enabled by the possibility of adjusting the conformation using the appropriate technique for their chemical synthesis. Therefore, expanding the toolkit for peptide cyclization is highly demanding for discovering new macrocycles endowed with unique properties.<sup>2,3</sup>

Nonetheless, cyclization of linear peptides remains a challenge since the activated peptide must adopt an entropically disfavoured pre-cyclization conformation before the desired intramolecular reaction can occur. Traditional methods for peptide cyclization rely on the intramolecular formation of ester, amide or disulphide bonds.<sup>4</sup> Alternatively, more recently, new approaches based on the use of Mannich,<sup>5</sup> Ugi,<sup>6</sup> Horner-Wadsworth-Emmons,<sup>7</sup> transition metal catalyzed processes,<sup>8</sup> and photocatalyzed transformations<sup>9</sup> have been developed.

Toward the generation of new engineered cyclic peptides, the introduction of non-peptide units in the cyclic structure has been used as a strategy for enhancing conformational rigidity and metabolic stability.<sup>1d</sup> For instance, several research groups have demonstrated that the incorporation of heterocyclic moieties into cyclic peptides has a positive influence on reaching the required binding conformation for biological interactions.<sup>10</sup> However, this type of cyclic peptides can be challenging to prepare using classical approaches. Therefore, methodologies that simultaneously cyclize and introduce one or more non-canonical backbone structures are highly appealing.


In this context, 1,3-dipolar cycloaddition, one of the most attractive synthetic routes to five membered heterocycles, displays a unique potential for the preparation of cyclic peptides containing heterocyclic scaffolds. However, as far as we are aware, only azide-alkyne 1,3-dipolar cycloaddition has been broadly used as a tool for peptide cyclization.<sup>11</sup>

Azomethine ylides have received particular attention as 1,3-dipoles because of the significance of the pyrrolidine ring which constitute the central structure of the proline amino acid and it is present in a plethora of natural products and catalysts.<sup>12</sup> Specifically, the metal catalyzed intramolecular 1,3-dipolar cycloaddition of azomethine ylide has emerged as a valuable tool for the preparation of pyrrolidine containing polycyclic natural products.<sup>13</sup>

In 2020 Guéret and Waldmann<sup>14</sup> developed an efficient methodology for the preparation of natural product-inspired cyclic peptide- hybrids on solid support by macrocyclization of the peptide chain via imine formation. The subsequent 1,3-dipolar cycloaddition in the presence of lithium bromide and Et<sub>3</sub>N efficiently delivered the corresponding adducts (Scheme 1).

On these grounds, building on the previous experience of our research group in 1,3-dipolar cycloadditions,<sup>15</sup> we set out the development of a new methodology for accessing to modified cyclic peptides based on a metal-catalyzed azomethine ylide intramolecular 1,3-dipolar cycloaddition process.

**Scheme 1. Late-stage functionalization of peptides via a 1,3-dipolar cycloaddition process**




To attain this goal, we were aware that two challenges needed to be addressed: (a) The effective coordination of the metal to the imino amide precursor of the azomethine ylide in the presence of numerous basic centres existing in the linear counterpart. (b) Achieved precise asymmetric control dictated by the stereogenic centres present in the peptide chain.

To reach our goal, we chose as model substrate the linear tripeptide **1a** decorated with an activated double bond at the side chain of the C-terminus and an azomethine ylide precursor at N-terminus.<sup>16</sup> Initially, we tested several of the most common conditions for 1,3-dipolar cycloadditions of azomethine ylide precursors (Table 1).<sup>17</sup> In these initial experiments, we were delighted to find that in the presence AgOAc as catalyst, 1,1'-bis(diphenylphosphino)ferrocene (dppf) as ligand and Et<sub>3</sub>N as base in CH<sub>2</sub>Cl<sub>2</sub> (0,06 M), the 11-membered-cyclopeptide **2a** was obtained in 51% isolated yield (entry 1). Remarkably, the reaction proceeded with excellent regio and stereocontrol since only the peptide **2a** with 2,3,5-*cis* configuration in the resulting pyrrolidine unit was obtained. In addition, the unreacted linear peptide was recovered unaltered and no oligomerisation

product was detected in the analysis of the reaction crude. Although result was slightly improved in the presence the monodentate ligand PPh<sub>3</sub> (61%, entry 2), the most significant increase in reactivity was observed using [(CH<sub>3</sub>CN)<sub>4</sub>Cu]PF<sub>6</sub> as the metal source (90%, entry 3). Similar results were obtained using KO<sup>t</sup>Bu as base (entry 4), but other bases or solvents gave poorer results.<sup>18</sup> Control experiments showed that ligand, base, and copper source were necessary to obtain high conversions (entries 5-7).

**Table 1. Optimization studies**



Entry	Metal	L	T (°C)	Yield (%) <sup>a</sup>
1	AgOAc	dppf	rt	51
2	AgOAc	PPh <sub>3</sub>	rt	61
3	[(CH <sub>3</sub> CN) <sub>4</sub> Cu]PF <sub>6</sub>	PPh <sub>3</sub>	rt	90
4 <sup>b</sup>	[(CH <sub>3</sub> CN) <sub>4</sub> Cu]PF <sub>6</sub>	PPh <sub>3</sub>	rt	88
5	[(CH <sub>3</sub> CN) <sub>4</sub> Cu]PF <sub>6</sub>	--	rt	33
6 <sup>c</sup>	[(CH <sub>3</sub> CN) <sub>4</sub> Cu]PF <sub>6</sub>	PPh <sub>3</sub>	rt	30
7	--	PPh <sub>3</sub>	rt	0
8	--	PPh <sub>3</sub>	80	0
9 <sup>d</sup>	[(CH <sub>3</sub> CN) <sub>4</sub> Cu]PF <sub>6</sub>	PPh <sub>3</sub>	rt	85

<sup>a</sup> Isolated yield after chromatographic purification. <sup>b</sup> KO<sup>t</sup>Bu as base. <sup>c</sup> No base. <sup>d</sup> 5 mol% of catalyst. dppf = 1,1'-bis(diphenylphosphino)ferrocene.


No reactivity was observed even when the reaction was carried out at higher temperature (80 °C) in the absence of the copper catalyst (entry 7). A slight drop in the yield was observed when the catalyst loading was reduced to 5 mol% (85%, entry 8). The configuration of cyclopeptide **2a** was unequivocally established by X-ray crystallographic analysis.<sup>19</sup>

With the optimized reaction conditions in hands, we next explored the generality of this intramolecular cycloaddition process regarding the substitution at the azomethine ylide precursor. A wide range of imino amides derived from aromatic aldehydes were examined (Scheme 2). The cycloaddition afforded selectively the corresponding cyclopeptides **2b-d** with good yields (87-92%) using imino amides either with electron-donating or electron-withdrawing substituents at the aromatic ring. Aromatic azomethine ylide precursors **1e-g** with *ortho*-, *meta*- or *para*- substituents provided similar results (cycloadducts **2e-g**). Substrates incorporating polycyclic aromatic hydrocarbons such as naphthyl **1h** and pyrenyl **1i** were found to be compatible in the cycloaddition process.

Notably, the fluorescence exhibit by the resulting polyaromatic-cyclopeptides highlight their potential utility as structural probes.<sup>20</sup>

The cycloaddition was equally effective with heteroaromatic-substituted imino amides such as indenyl **1j**, thienyl **1k**, and pyridyl **1l** (cycloadducts **2j-l**). Remarkably, cyclopeptides decorated with pyrrolidines containing a quaternary stereocenter in position 2 can also be prepared using this methodology. Thus, cycloadducts bearing proline derivatives with either methyl (**2m**), benzyl (**2n**) or (methylthio)ethyl (**2o**) substituents at C-2 were isolated with high yield and diastereoselectivity.

**Scheme 2. Scope regarding azomethine ylide precursor<sup>a</sup>**




<sup>a</sup> Isolated yield after chromatographic purification. <sup>b</sup> KO<sup>t</sup>Bu instead of Et<sub>3</sub>N.

Next, we turned our attention to establish the scope of the methodology regarding the peptide chain. As shown in Scheme 3, the switch of threonine for serine results in excellent reaction efficacy and diastereoselectivity (cyclopeptide **4a**, 82%). Likewise, its switch for 4-hydroxyproline smoothly led to the cyclic peptide **4b** containing three proline units, although with lower yield (48%).

The presence of turn-induce elements such as proline in the peptide chain is usually critical for preorganized peptides for the cyclization. In fact, the reaction of linear peptide **3d** with a glycine instead of proline did not afford the macrocyclization product (**4c**). However, we were pleased to find that when the sarcosine was used instead of glycine the reaction took place with excellent yield (**4d**, 78%). The use of substrates containing Phe and Val residues resulted in efficient macrocyclization [**4e** (85%) and **4f** (80%)].


### Scheme 3. Scope regarding the peptide chain<sup>a</sup>



<sup>a</sup> Isolated yield after chromatographic purification.

Next, we studied the compatibility of the procedure regarding other dipolarophiles (Scheme 4). The use of a linear peptide precursor with a *trans* deactivated olefin derived from fumarate (**5a**) provided the corresponding macrocycle **6a** in 86% yield. The reaction also showed compatibility with a phenyl group in the  $\beta$ -position of the  $\alpha,\beta$ -unsaturated ester (**6b**, 89% yield). Additionally, the sulfonyl precursor **5c** proved to be an excellent substrate, affording the corresponding adduct with almost complete diastereoselectivity and an excellent yield (**6c**, 84%).


### Scheme 4. Scope with respect to the dipolarophile<sup>a</sup>



Finally, we explored the range of different ring size that could be assembled using this methodology (Scheme 5). We found that this methodology is not suitable for the cyclization of shorter peptide chains (8 atoms) (Scheme 5, **8a**) which aligns with the inherent stability of the amide *trans*-conformation. However, in addition to the 11-membered cycles shown in Schemes 2-4, peptides sequences containing 14, 17 and 23

atoms (**7b-d**, respectively) effectively underwent the cycloaddition reaction using the optimized reaction conditions [**8b** (62%), **8c** (68%), and **8d** (76%)].


**Scheme 5. Scope regarding peptide macrocycle ring size<sup>a</sup>**



<sup>a</sup> Isolated yield after chromatographic purification.

To elucidate the mechanistic details of the cyclization step, DFT calculations were performed by employing the linear tripeptide **1a** and the ligand PPh<sub>3</sub> to model the possible reaction intermediates by coordination to a Cu<sup>I</sup> atom from the catalyst (Figure 1). Most likely, the bidentate coordination (through N and O1) of **1a** to the Cu(I) would favor the *in situ* generation of the azomethine ylide leading to complex **I**. In this complex, due to the simultaneous coordination of PPh<sub>3</sub>, that generates both steric and  $\pi$ -stacking interactions with the tripeptide, the linear structure adopts an optimal conformation allowing the coordination of the carbonyl group (through O2) at the sidechain of the C-terminus to the Cu<sup>I</sup> center, fixing the *endo* approach (distances around Cu atom remain almost constant throughout the process, see SI for details). This preorganization would arrange the dipolarophile moiety at an angle and a distance appropriate for the 1,3-dipolar reaction to proceed efficiently. Thus, the formation of the C1–C2 bond between the benzylic position of the ylide part and the alkene unit *via* **TS-I-II** (12.8 kcal·mol<sup>-1</sup>) would lead to the formation of the zwitterionic intermediate **II** (6.9 kcal·mol<sup>-1</sup>), followed by subsequent cyclization [the second C3–C4 bond formed *via* **TS II-III** (7.9 kcal·mol<sup>-1</sup>)] to afford the cycloaddition product **III** (-5.6 kcal·mol<sup>-1</sup>). Therefore, according to these computational studies, the cyclization should proceed through a stepwise mechanism. The low activation barriers and the structure of complexes account for the relatively fast reaction and complete *endo*-diastereoselectivity experimentally observed.

In summary, we present an efficient and selective methodology for cyclizing peptides via intramolecular Cu-catalyzed (3+2) cycloaddition of azomethine ylides. This approach allows the incorporation of proline moieties with up to four new chiral centers into the macrocycle, achieving excellent yields and complete diastereocontrol. The cycloaddition is compatible with a range of natural amino acids, various macrocyclic sizes, and different dipolarophiles.



**Figure 1.** Free energy profile for the Cu-catalyzed 1,3-dipolar cycloaddition of 1a. (M06/6-311++G(d,p) (C,H,N,O,P), LANL2TZ(f) (Cu)/SMD(CH<sub>2</sub>Cl<sub>2</sub>)//B3LYP-D3/6-31G(d) (C,H,N,O,P), LANL2DZ(f) (Cu)). Relative G values at 298 K (kcal·mol<sup>-1</sup>) and representative distances (Å) are indicated.

## ASSOCIATED CONTENT

The Supporting Information is available free of charge at <https://pubs.acs.org>.

Supplementary figures and tables; detailed materials and methods; full experimental procedures and analytical data for all the listed reactants and products; and computational data (PDF).

## AUTHOR INFORMATION

### Corresponding Authors

\*E-mail: [n.rodriguez@uam.es](mailto:n.rodriguez@uam.es)

\*E-mail: [javier.adrio@uam.es](mailto:javier.adrio@uam.es)

### ORCID

Nuria Rodríguez: 0000-0002-7174-4555

Javier Adrio: 0000-0001-6238-6533

### Author Contributions

The manuscript was written through contributions of all authors. / All authors have given approval to the final version of the manuscript.

### Funding Sources

FEDER/Ministerio de Ciencia, Innovación y Universidades–Agencia Estatal de Investigación PID2021-1248553NB-100.

### Notes

The authors declare no competing financial interest.

## ACKNOWLEDGMENT

We thank FEDER/Ministerio de Ciencia, Innovación y Universidades–Agencia Estatal de Investigación (PID2021-1248553NB-100, RED2022-134331-T and RED2022-134287-



T) for financial support. E. G. thanks MICIU for a FPI predoctoral fellowship. We also thank the CCC-UAM for their generous allocation of computer time.

## REFERENCES

- (1) (a) Ji, X.; Nielsen, A. L.; Heinis, C. Cyclic Peptides for Drug Development. *Angew. Chem. Int. Ed.* **2024**, *63*, e202308251. (b) Oppewal, T. R.; Jansen, I. D.; Hekelaar, J.; Mayer, C. A Strategy to Select Macrocyclic Peptides Featuring Asymmetric Molecular Scaffolds as Cyclization Units by Phage Display. *J. Am. Chem. Soc.* **2022**, *144*, 3644-3652. (c) Muttenthaler, M.; King, G. F.; Adams, D. J.; Alewood, P. F. Trends in Peptide Drug Discovery, *Nat. Rev. Drug Discov.* **2021**, *20*, 309-325. (d) Gotoand, Y.; Suga, H. The RaPID Platform for the Discovery of Pseudo-Natural Macrocyclic Peptides. *Acc. Chem. Res.* **2021**, *54*, 3604-3617. (e) Vinogradov, A. A.; Yin, Y.; Suga, H. Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges. *J. Am. Chem. Soc.* **2019**, *141*, 4167-4181. (f) Zorzi, A.; Deyle, K.; Heinis, C. Cyclic Peptide Therapeutics: Past, Present and Future. *Curr. Opin. Chem. Biol.* **2017**, *38*, 24-29.
- (2) (a) Capecchi, A.; Reymond, J.-L. Peptides in Chemical Space. *Medicine in Drug Discovery*, **2021**, *9*, 100081. (b) Díaz-Eufracio, B. I.; Palomino-Hernández, O.; Houghten, R. A.; Medina-Franco, J. L. Exploring the Chemical Space of Peptides for Drug Discovery: a Focus on Linear and Cyclic Pentapeptides. *Mol. Divers.* **2018**, *22*, 259-267.
- (3) Bechtler, C.; Lamers, C. Macrocyclization Strategies for Cyclic Peptides and Peptidomimetics. *RSC Med. Chem.* **2021**, *12*, 1325-1351.
- (4) (a) He, R.; Pan, J.; Mayer, J. P.; Liu, F. Stepwise Construction of Disulfides in Peptides. *ChemBioChem* **2020**, *21*, 1101-1111. (b) White, C.; Yudin, A. Contemporary Strategies for Peptide Macrocyclization. *Nature Chem.* **2011**, *3*, 509-524.
- (5) Yamaguchi, A.; Kaldas, S. J.; Appavoo, S. D.; Diaz, D. B.; Yudin, A. K. Conformationally Stable Peptide Macrocycles Assembled Using the Petasis Borono-Mannich Reaction. *Chem. Commun.* **2019**, *55*, 10567-10570.
- (6) Wessjohann, L. A.; Kreye, O.; Rivera, D. G. One-Pot Assembly of Amino Acid Bridged Hybrid Macromulticyclic Cages through Multiple Multicomponent Macrocyclizations. *Angew. Chem. Int. Ed.* **2017**, *56*, 3501-3505.
- (7) Harrison, J. R.; Moody, C. J. The Horner–Wadsworth–Emmons Reaction in the Synthesis of Macrocyclic Peptides: the Trp-His-Gly-Arg Derived Macrocycle of Moroidin. *Tetrahedron Lett.* **2003**, *44*, 5189-5191.
- (8) Rivera, D. G.; Ojeda-Carralero, G. M.; Reguera, L.; Van der Eycken, E. V. Peptide Macrocyclization by Transition Metal Catalysis. *Chem. Soc. Rev.* **2020**, *49*, 2039-2059.
- (9) Raynal, L.; Rose, N. C.; Dr. James R. Donald, Christopher D. Spice. Photochemical Methods for Peptide Macrocyclisation. *Chem. Eur. J.* **2021**, *27*, 69-88.
- (10) Kaldas, S. J.; Yudin, A. K. Achieving Skeletal Diversity in Peptide Macrocycles through The Use of Heterocyclic Grafts. *Chem. Eur. J.* **2018**, *24*, 7074-7082.
- (11) (a) Xu, W.; Lau, Y. H.; Fischer, G.; Tan, S. Y.; Chattopadhyay, A.; de la Roche, M.; Hyvönen, M.; Verma, C.; Spring, D. R.; Itzhaki, L. S. Macrocyclized Extended Peptides: Inhibiting the Substrate-Recognition Domain of Tankyrase. *J. Am. Chem. Soc.* **2017**, *139*, 2245-2256. (b) Jagasia, R.; Holub, J. M.; Bollinger, M.; Kirshenbaum, K.; Finn, M. G. Peptide Cyclization and Cyclodimerization by Cu<sup>I</sup>-Mediated Azide–Alkyne Cycloaddition. *J. Org. Chem.* **2009**, *74*, 2964-2974.
- (12) For recent reviews, see: (a) Kumar, S. V.; Guiry, P. J. Catalytic Enantioselective [3+2] Cycloaddition of *N*-Metalated Azomethine Ylides. *Chem. Eur. J.* **2023**, *29*, e202300296. (b) Wei, L.; Chang, X.; Wang, C. J. Catalytic Asymmetric Reactions with *N*-Metalated Azomethine Ylides. *Acc. Chem. Res.* **2020**, *53*, 1084-1100. (c) Adrio, J.; Carretero, J. C. Stereochemical Diversity in Pyrrolidine Synthesis by Catalytic Asymmetric 1, 3-Dipolar Cycloaddition of Azomethine Ylides. *Chem. Commun.* **2019**, *55*, 11979-11991. (d) Nájera, C.; Sansano, J. M. Synthesis of Pyrrolizidines and Indolizidines by Multicomponent 1,3-Dipolar Cycloaddition of Azomethine Ylides. *Pure Appl. Chem.* **2019**, *91*, 575-596. (e) Arrastia, I.; Arrieta, A.; Cossio, F. P. Application of 1, 3-Dipolar Reactions between Azomethine Ylides and Alkenes to the Synthesis of Catalysts and Biologically Active Compounds. *Eur. J. Org. Chem.* **2018**, *43*, 5889-5904. For selected recent references, see: (f) Liou, Y.-C.; Chen, Y.-R.; Hsu, C.-W.; Huang, X.-R.; Wang, H.-W.; Lin, W. Alkylidene Meldrum's Acid as Acceptor-Donor-Acceptor with Azomethine Ylide for Organocatalytic Asymmetric [3+2] Cycloaddition/Annulation: Synthesis of Chromeno[4,3-*b*]pyrrolidine. *Adv. Synth. Catal.* **2023**, *365*, 3603-3610. (g) Chen, Z.; Zhong, W.; Liu, S.; Zou, T.; Zhang, K.; Gong, C.; Guo, W.; Kong, F.; Nie, L.; Hu, S.; Wang, H. Highly Stereodivergent Synthesis of Chiral C4-Ester-Quaternary Pyrrolidines: A Strategy for the Total Synthesis of Spirotryprostatin A. *Org. Lett.* **2023**, *25*, 3391-3396. (h) Wang, B.-R.; Li, Y.-B.; Zhang, Q.; Gao, D.; Tian, P.; Li, Q.; Yin, L. Copper(I)-catalyzed Asymmetric 1,3-Dipolar Cycloaddition of 1,3-enynes and Azomethine Ylides. *Nat. Commun.* **2023**, *14*, 4688-4699.
- (13) (a) Panda, S. S.; Aziz, M. N.; Stawinski, J.; Girgis, A. S. Azomethine Ylides Versatile Synthons for Pyrrolidinyl-Heterocyclic Compounds. *Molecules* **2023**, *28*, 668-749. (b) Coldham, I.; Hufton, R. Intramolecular Dipolar Cycloaddition Reactions of Azomethine Ylides. *Chem. Rev.* **2005**, *105*, 2765-2810. (c) Cristóbal, C.; Gaviña, D.; Alonso, I.; Ribagorda, M.; Carretero, J. C.; del Pozo, C.; Adrio, J. Catalytic Enantioselective Intramolecular 1,3-Dipolar Cycloaddition of Azomethine Ylides with



- Fluorinated Dipolarophiles. *Chem. Commun.* **2022**, *58*, 7805-7808. (d) Liu, J.; Zhang, R.; Mallick, S.; Patil, S.; Wientjens, C.; Flegel, J.; Krupp, A.; Strohmann, C.; Grassin, C.; Merten, C.; Pahl, A.; Grigalunas, M.; Waldmann, H. A Highly Enantioselective Intramolecular 1,3- Dipolar Cycloaddition Yields Novel Pseudo-Natural Product Inhibitors of the Hedgehog Signalling Pathway. *Chem. Sci.* **2023**, *14*, 7936-7943.
- (14) Guéret, S. M.; Thavam, S.; Carbajo, R. J.; Potowski, M.; Larsson, N.; Dahl, G.; Dellsén, A.; Grossmann, T. N.; Plowright, A. T.; Valeur, E.; Lemurell, M.; Waldmann, H. Macrocyclic Modalities Combining Peptide Epitopes and Natural Product Fragments. *J. Am. Chem. Soc.* **2020**, *142*, 4904-4915.
- (15) (a) Maclean, I.; Gallent, E.; Orozco, O.; Molina, A.; Rodríguez, N.; Adrio, J.; Carretero, J. C. Atroposelective Synthesis of Axially Chiral Naphthylpyrroles by a Catalytic Asymmetric 1,3-Dipolar Cycloaddition/Aromatization Sequence. *Org. Lett.* **2024**, *26*, 922-927. (b) Cristóbal, C.; Corral, C.; Carretero, J. C.; Ribagorda, M.; Adrio, J. Enantioselective transformations of 5-hydroxymethylfurfural *via* catalytic asymmetric 1,3-dipolar cycloaddition of azomethine ylides. *Chem. Commun.* **2023**, *59*, 4336-4639. (c) Corpas, J.; Ponce, A.; Adrio, J.; Carretero, J. C. Cu<sup>I</sup>-Catalyzed Asymmetric [3+2] Cycloaddition of Azomethine Ylides with Cyclobutenones. *Org. Lett.*, **2018**, *20*, 3179–3182.
- (16) See Supporting Information for details of linear precursors synthesis.
- (17) For the use of iminoamides as azomethine ylide precursor, see: (a) González-Esguevillas, M.; Adrio, J.; Carretero, J. C. Cu-Catalyzed Asymmetric [3+2] Cycloaddition of  $\alpha$ -Iminoamides with Activated Olefins. *Chem. Commun.* **2012**, *48*, 2149-2151. During the preparation of this manuscript a [3+2] cycloaddition of linear peptides and maleimides have been reported: (b) Machida, H.; Kanemoto, K. *N*-Terminal-Specific Dual Modification of Peptides through Copper-Catalyzed [3+2] Cycloaddition. *Angew. Chem. Int. Ed.* **2024**, *63*, e2023200.
- (18) See Supporting Information for further details.
- (19) The relative configuration of the cyclopeptides was determined by X-ray diffraction analysis of **2a**. CCDC 2363184 contains the supplementary crystallographic data [www.ccdc.cam.ac.uk/data\\_request/cif](http://www.ccdc.cam.ac.uk/data_request/cif).
- (20) Ayyavoo, K.; Velusamy, P. Pyrene Based Materials as Fluorescent Probes in Chemical and Biological Fields. *New J. Chem.* **2021**, *45*, 10997-11017.